Lempereur, Mathieu ; Université de Liège - ULiège > Département des sciences cliniques
Davin, Laurent ; Université de Liège - ULiège > Département des sciences cliniques
Viva, Tommaso; Department of Cardiology, CHU Sart Tilman, GIGA Institutes - Cardiovascular Sciences and Metabolism, University of Liège Hospital, Belgium ; University of Milano, Milan, Italy and IRCCS Galeazzi - Sant'Ambrogio Hospital, Department of Minimally Invasive Cardiac Surgery, Milan, Italy
Vahanian A, Beyersdorf F, Praz F, et al.2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2022;43(7):561–632. doi: 10.1093/eurheartj/ehab395.
Postolache A, Sperlongano S, Lancellotti P., TAVI after more than 20 years. J Clin Med. 2023;12(17):5645. doi: 10.3390/jcm12175645.
Masson J-B, Kovac J, Schuler G, et al.Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc Interv. 2009;2(9):811–820. doi: 10.1016/j.jcin.2009.07.005.
Scarsini R, De Maria GL, Joseph J, et al.Impact of complications during transfemoral transcatheter aortic valve replacement: how can they be avoided and managed?J Am Heart Assoc. 2019;8(18):e013801. doi: 10.1161/JAHA.119.013801.
Vincentelli A, Susen S, Le Tourneau T, et al.Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349(4):343–349. doi: 10.1056/NEJMoa022831.
De Larochellière H, Puri R, Eikelboom JW, et al.Blood disorders in patients undergoing transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(1):1–11. doi: 10.1016/j.jcin.2018.09.041.
Kibler M, Marchandot B, Messas N, et al.Primary hemostatic disorders and late major bleeding after transcatheter aortic valve replacement. J Am Coll Cardiol. 2018;72(18):2139–2148. doi: 10.1016/j.jacc.2018.08.2143.
Van Belle E, Rauch A, Vincent F, et al.Von Willebrand factor multimers during transcatheter aortic-valve replacement. N Engl J Med. 2016;375(4):335–344. doi: 10.1056/NEJMoa1505643.
Varghese SS, Hetu M-F, Bowman M, et al.Impact of transcatheter aortic valve implantation on circulating von Willebrand factor in patients with severe aortic stenosis. Haemophilia. 2023;29(5):1306–1312. doi: 10.1111/hae.14825.
Correction of acquired von Willebrand syndrome by transcatheter aortic valve implantation. [accessed November 26, 2024]. Available from: https://www.hmpgloballearningnetwork.com/site/jic/articles/correction-acquired-von-willebrand-syndrome-transcatheter-aortic-valve-implantation.
Mehran R, Rao SV, Bhatt DL, et al.Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123(23):2736–2747. doi: 10.1161/CIRCULATIONAHA.110.009449.
Jiménez-Xarrié E, Asmarats L, Roqué-Figuls M, et al.Impact of baseline anemia in patients undergoing transcatheter aortic valve replacement: a prognostic systematic review and meta-analysis. J Clin Med. 2023;12(18):6025. doi: 10.3390/jcm12186025.
Takagi H, Hari Y, Kawai N, et al.Meta-analysis of impact of anemia and hemoglobin level on survival after transcatheter aortic valve implantation. Am J Cardiol. 2019;123(2):306–314. doi: 10.1016/j.amjcard.2018.09.042.
Kalińczuk Ł, Zieliński K, Chmielak Z, et al.Effect on mortality of systemic thromboinflammatory response after transcatheter aortic valve implantation. Am J Cardiol. 2019;124(11):1741–1747. doi: 10.1016/j.amjcard.2019.08.036.
Sexton TR, Wallace EL, Chen A, et al.Thromboinflammatory response and predictors of outcomes in patients undergoing transcatheter aortic valve replacement. J Thromb Thrombolysis. 2016;41(3):384–393. doi: 10.1007/s11239-015-1326-z.
Al-Kindi SG, Attizzani GF, Decicco AE, et al.Lymphocyte counts are dynamic and associated with survival after transcatheter aortic valve replacement. Struct. Heart. 2018;2(6):557–564. doi: 10.1080/24748706.2018.1522680.
Gallet R, Seemann A, Yamamoto M, et al.Effect of transcatheter (via femoral artery) aortic valve implantation on the platelet count and its consequences. Am J Cardiol. 2013;111(11):1619–1624. doi: 10.1016/j.amjcard.2013.01.332.
Mitrosz M, Chlabicz M, Hapaniuk K, et al.Thrombocytopenia associated with TAVI—the summary of possible causes. Adv Med Sci. 2017;62(2):378–382. doi: 10.1016/j.advms.2017.04.003.
Jilaihawi H, Doctor N, Chakravarty T, et al.Major thrombocytopenia after balloon-expandable transcatheter aortic valve replacement: prognostic implications and comparison to surgical aortic valve replacement. Catheter Cardiovasc Interv. 2015;85(1):130–137. doi: 10.1002/ccd.25430.
Von Willebrand factor and management of heart valve disease. [accessed January 3, 2024]. Available from: https://www.jacc.org/doi/epdf/10.1016/j.jacc.2018.12.045.
Ramesh P, Kanagalingam S, Zargham Ul Haq F, et al.Acquired Von Willebrand deficiency in adults with aortic stenosis: a systematic review. Cureus. 2022;14(9):e28879. doi: 10.7759/cureus.28879.
Sedaghat A, Kulka H, Sinning J-M, et al.Transcatheter aortic valve implantation leads to a restoration of von Willebrand Factor (VWF) abnormalities in patients with severe aortic stenosis–incidence and relevance of clinical and subclinical VWF dysfunction in patients undergoing transfemoral TAVI. Thromb Res. 2017;151:23–28. doi: 10.1016/j.thromres.2016.12.027.
Van Belle E, Rauch A, Vincentelli A, et al.Von willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions. Circ Res. 2015;116(7):1193–1201. doi: 10.1161/CIRCRESAHA.116.305046.
